# A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment

> **NCT01767948** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 30 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** PCI-32765

## Key facts

- **NCT ID:** NCT01767948
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2014-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01767948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01767948, "A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01767948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*